IRAK4-IN-21 (化合物 17) 是一种口服有效的和具有选择性的强效IRAK4抑制剂,其对IRAK4和TAK1的IC50值分别为 5 和 56 nM。IRAK4-IN-21 能够有效抑制 IL-23 的产生 (IC50=0.17 μM),可用于自身免疫性疾病,如斑块状银屑病和银屑病关节炎的研究。
生物活性 | IRAK4-IN-21 (compound 17) is an orally active, potent and selectiveIRAK4inhibitor withIC50values of 5 and 56 nM forIRAK4andTAK1, respectively. IRAK4-IN-21 effectively inhibitsIL-23production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis[1]. |
体外研究 (In Vitro) | IRAK4-IN-21 (a 4-fold serial dilution from 10 μM; 1 h) decreases the levels of IL-23 (in THP-1 and DC cells), IL-6 (in HUVEC cells) and MIP-1β (in human whole blood)[1].
Cell Viability Assay[1] Cell Line: | THP-1, DC cells (are primed with IFN-γ) | Concentration: | 10 μM (a 4-fold serial dilution from 10 μM) | Incubation Time: | 1 h (pre-incubate) | Result: | Inhibited the levels of IL-23 in the supernatant of THP-1 and DC cells with IC50of 0.17 and 0.51 μM, respectively. |
Cell Viability Assay[1] Cell Line: | HUVEC cells (IL-1β-stimulated) | Concentration: | 10 μM (a 4-fold serial dilution from 10 μM) | Incubation Time: | 1 h (pre-incubate) | Result: | Inhibited the level of IL-6 in the supernatant of HUVEC cells with an IC50of 0.20 μM. |
Cell Viability Assay[1] Cell Line: | Human whole blood (IL-1β-stimulated) | Concentration: | 10 μM (a 4-fold serial dilution from 10 μM) | Incubation Time: | 1 h (pre-incubate) | Result: | Inhibited the level of MIP-1β in the human whole blood with an IC50of 0.47 μM. |
|
体内研究 (In Vivo) | IRAK4-IN-21 (75 mg/kg; p.o.; single) shows moderate efficacy in acute animal model studies for the inhibition of IL-6 production[1].
Animal Model: | BALB/c mice (acute mouse model; IL-1β-stimulated)[1]. | Dosage: | 75 mg/kg | Administration: | Oral administration; single (pre-treat). | Result: | Showed 54% inhibition of IL-6, plasma concentrations was 2877 ng/mL at 0.5 h and 496 ng/mL at 2 h. |
|
分子量 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |